(Q35117241)

English

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan

scientific article published on May 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

1 reference

Europe PubMed Central

Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan (English)

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Managing the Risks of Prostate Disease During Testosterone Replacement Therapy in Older Men: Recommendations for a Standardized Monitoring Plan (English)

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

1 reference

based on heuristic

inferred from title

prostate disease

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Shalender Bhasin

1

object named as

Shalender Bhasin

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

author name string

Ricky Phong Mac

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Ballentine Carter

4

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Atam B. Singh

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721204

28 December 2023

Martin I. Lee

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721204

28 December 2023

Glenn R. Cunningham

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721204

28 December 2023

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12721204

28 December 2023

publication date

1 May 2003

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

full work available at URL

http://www.andrologyjournal.org/cgi/content/abstract/24/3/299

online access status

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12721204

28 December 2023

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fj.1939-4640.2003.tb02676.x

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

https://onlinelibrary.wiley.com/doi/pdf/10.1002/j.1939-4640.2003.tb02676.x

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Journal of Andrology

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

299-311

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

Blood hormone profiles in prostate cancer patients in high-risk and low-risk populations

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Serum pituitary and sex steroid hormone levels in the etiology of prostatic cancer--a population-based case-control study

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? Part II: Early detection strategies

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

LHRH analogues in combination with an anti-androgen in the treatment of advanced disease.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Effect of exogenous testosterone replacement on prostate-specific antigen and prostate-specific membrane antigen levels in hypogonadal men.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Low levels of prostate-specific antigen predict long-term risk of prostate cancer: results from the Baltimore Longitudinal Study of Aging

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Prospective study of sex hormone levels and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

The CAG repeat within the androgen receptor gene and its relationship to prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Cancer statistics, 2000.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Testosterone treatment in hypogonadal men: prostate-specific antigen level and risk of prostate cancer

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Oral testosterone replacement in Korean patients with PADAM.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Trends and patterns of prostate cancer: what do they suggest?

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

International trends and patterns of prostate cancer incidence and mortality

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Effects of androgen deficiency and replacement on prostate zonal volumes

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Declining gonadal function in elderly men.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Effects of transdermal testosterone on bone and muscle in older men with low bioavailable testosterone levels

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Cancer statistics, 1998.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Cancer statistics, 1999.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Evidence for an association between the SRD5A2 (type II steroid 5 alpha-reductase) locus and prostate cancer in Italian patients.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Andropause: clinical implications of the decline in serum testosterone levels with aging in men.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Prostate size in hypogonadal men treated with a nonscrotal permeation-enhanced testosterone transdermal system

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. International Society for the Study of the Aging Male

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Age-specific reference ranges for serum prostate-specific antigen in black men.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Occult prostate cancer in men with low serum testosterone levels

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Longitudinal changes in testosterone, luteinizing hormone, and follicle-stimulating hormone in healthy older men.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Analysis of variation in prostate-specific antigen values

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Androgen-primed chemotherapy-experimental confirmation of efficacy

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Volume change of the prostate and seminal vesicles in male hypogonadism after androgen replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

High-grade prostate cancer is associated with low serum testosterone levels

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Hormonal predictors of prostate cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Effect of testosterone replacement therapy on serum PSA in patients with Klinefelter syndrome

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Testosterone: its role in development of prostate cancer and potential risk from use as hormone replacement therapy

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Construction and field validation of a self-administered screener for testosterone deficiency (hypogonadism) in ageing men.

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

The effect of parenteral testosterone replacement on prostate specific antigen in hypogonadal men with erectile dysfunction

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Effects of testosterone and growth hormone on muscle function

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer

1 reference

https://api.crossref.org/works/10.1002%2FJ.1939-4640.2003.TB02676.X

21 January 2018

Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls

9

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma

10

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

The development of human benign prostatic hyperplasia with age

11

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Effects of testosterone replacement with a nongenital, transdermal system, Androderm, in human immunodeficiency virus-infected men with low testosterone levels

13

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Testosterone dose-response relationships in healthy young men.

15

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Prostate-specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity

18

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Clinical evidence for and implications of the multistep development of prostate cancer

19

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

PSA, PSA density, PSA density of transition zone, free/total PSA ratio, and PSA velocity for early detection of prostate cancer in men with serum PSA 2.5 to 4.0 ng/mL

25

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

PSA velocity for assessing prostate cancer risk in men with PSA levels between 2.0 and 4.0 ng/ml

29

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

The Response of Metastatic Adenocarcinoma of the Prostate to Exogenous Testosterone

31

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Prostate carcinoma: an autopsy evaluation of the influence of age, tumor grade, and therapy on tumor biology.

34

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis

43

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Is low serum free testosterone a marker for high grade prostate cancer?

48

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Effect of long-term oral testosterone undecanoate treatment on prostate volume and serum prostate-specific antigen concentration in eugonadal middle-aged men

49

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Serological precursors of cancer: serum hormones and risk of subsequent prostate cancer

52

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Serum hormone levels among patients with prostatic carcinoma or benign prostatic hyperplasia and clinic controls

56

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Characterization of prostatic carcinoma among blacks: a continuation report

58

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Pitfalls in interpreting prostate specific antigen velocity

62

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

The effects of prostatic manipulation on prostate-specific antigen levels

66

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Androgen priming and chemotherapy in advanced prostate cancer: evaluation of determinants of clinical outcome

69

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Diagnostic Significance of Prostate-Specific Antigen Velocity at Intermediate PSA Serum Levels in Relation to the Standard Deviation of Different Test Systems

70

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Estradiol and testosterone metabolism and production in men with prostatic cancer

75

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Familial prostatic cancer risk and low testosterone

76

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Effects of testosterone replacement therapy in old hypogonadal males: a preliminary study

83

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Prediagnostic serum hormones and the risk of prostate cancer

85

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers

88

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Effects of gonadotropin and testosterone treatments on prostate volume and serum prostate specific antigen levels in male hypogonadism

89

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Pharmacokinetics of a transdermal testosterone system in men with end stage renal disease receiving maintenance hemodialysis and healthy hypogonadal men.

101

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Rate of Change in Serum Prostate Specific Antigen Levels as a Method For Prostate Cancer Detection

103

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Effect of testosterone treatment on bone mineral density in men over 65 years of age.

106

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Testosterone administration to elderly men increases skeletal muscle strength and protein synthesis

112

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Variation in PSA values in patients without malignancy

115

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Prospective study of sex hormone levels and risk of prostate cancer

116

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. World Health Organization Task Force on Methods for the Regulation of Male Fertility.

118

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Longitudinal relation between endogenous testosterone and cardiovascular disease risk factors in middle-aged men. A 13-year follow-up of former Multiple Risk Factor Intervention Trial participants

119

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Abnormal levels of plasma hormones in men with prostate cancer: evidence toward a "two-disease" theory

120

1 reference

10.1002/J.1939-4640.2003.TB02676.X

https://api.crossref.org/works/10.1002/J.1939-4640.2003.TB02676.X

28 December 2023

Identifiers

10.1002/J.1939-4640.2003.TB02676.X

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

6 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35117241&oldid=2039399194"